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ABSTRACT
Opiates were the first drugs shown to negatively impact neuro-
genesis in the adult mammalian hippocampus. Literature data
also suggest that norepinephrine is a positive modulator of
hippocampal neurogenesis in vitro and in vivo. On the basis of
these observations, we investigated whether tapentadol, a novel
central analgesic combining m-opioid receptor (MOR) agonism
with norepinephrine reuptake inhibition (NRI), may produce less
inhibition of hippocampal neurogenesis comparedwithmorphine.
When tested in vitro, morphine inhibited neuronal differentiation,
neurite outgrowth, and survival of adult mouse hippocampal
neural progenitors and their progeny, via MOR interaction. By
contrast, tapentadol was devoid of these adverse effects on cell
survival and reduced neurite outgrowth and the number of newly
generated neurons only at nanomolar concentrations where the
MOR component is predominant. On the contrary, at higher
(micromolar) concentrations, tapentadol elicited proneurogenic
and antiapoptotic effects via activation of b2 and a2 adrenergic
receptors, respectively. Altogether, these data suggest that the
noradrenergic component in tapentadol has the potential to
counteract the adverse MOR-mediated effects on hippocampal
neurogenesis. As a proof of concept, we showed that reboxetine,
an NRI antidepressant, counteracted both antineurogenic and
apoptotic effects of morphine in vitro. In line with these obser-
vations, chronic tapentadol treatment did not negatively affect
hippocampal neurogenesis in vivo. In light of the increasing long-
term use of opiates in chronic pain, in principle, the tapentadol
combined mechanism of action may result in less or no reduction
in adult neurogenesis compared with classic opiates.
Introduction
Clinical research has shown that opiate addicts display
deficits inmemory tasks, attention, verbal fluency, and general
cognitive performance, relative to controls (Cipolli and Gal-
liani, 1987; Guerra et al., 1987; Gruber et al., 2007). The pos-
sibility that chronic opiate treatment in nonaddicted patients
may also cause cognitive impairment in the long term is
controversial, but is of considerable clinical interest (Kendall
et al., 2010; Kurita et al., 2011; Højsted et al., 2012). Although
the central depressant effects of opiates complicate the in-
terpretation of drug effects on cognition, evidence from basic
research contributes to the idea that chronically administered
opiates may interfere with cognition independently of perfor-
mance effects. In rodents, chronic morphine treatment resulted
in impaired acquisition of radial maze and Y-maze choice
escape tasks, but did not alter performance of the task if it was
learned before drug exposure (Spain and Newsom, 1991).
Moreover, in animal models, dependence on morphine did not
impair learning ability in the reference memory version of the
water Morris maze, but partially impaired memory retention
for the previously learned spatial information (Miladi Gorji
et al., 2008). These findings suggest that long-term opiate use
may produce maladaptive changes in brain structures involved
in learning andmemory, such as the hippocampus. Underlying
mechanisms for a disruption of long-term memory retention in
morphine-dependent animals have been suggested to rely on
impairment in hippocampal long-term potentiation (Pu et al.,
2002), but other mechanisms may play a role and deserve
exploration. An intriguing property of the adult hippocampal
dentate gyrus (DG) is its ability to generate new neurons
throughout life, a process referred to as adult neurogenesis. In
particular, new cells are born in the subgranular zone (SGZ) of
the DG, where resident neural stem cells can self-renew or give
rise to nestin-positive transiently amplifying progenitor cells
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hydroxy)phenoxy)ethylamino]-3-[4-(1-methyl-4-trifluoromethyl-2-imidazolyl)phenoxy]-2-propanol dihydrochloride; CTOP, D-Phe-Cys-Tyr-D-Trp-Orn-Thr-
Pen-Thr-NH2; DG, dentate gyrus; GCL, granular cell layer; GFAP, glial fibrillary acidic protein; ICI 118,551, 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]
butan-2-ol; MAP-2, microtubule-associated protein-2; MOR, m-opioid receptor; NE, norepinephrine; NET, norepinephrine transporter; NeuN, neuronal
nuclei; NPC, neural progenitor cell; NRI, norepinephrine reuptake inhibition; PBS, phosphate-buffered saline; PCR, polymerase chain reaction;
RT, reverse transcription; SGZ, subgranular zone.
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that, in turn, can generate neuroblasts capable of terminal
neuronal differentiation (Kempermann et al., 2003, 2004; Seri
et al., 2004; Bonaguidi et al., 2012). Finally, their postmitotic
neuronal progeny can integrate into the adult hippocampal
circuitry or it can be deleted by apoptosis (Deng et al., 2010).
Each step of adult neurogenesis is regulated and it has been
postulated to affect hippocampal function in the uninjured
brain (Zhao et al., 2008). Interestingly, it has been proposed
that new neurons born in the adult hippocampus may con-
tribute to a variety of hippocampal-related functions, including
learning and memory (Shors et al., 2001; Aimone et al., 2006,
2011; Denis-Donini et al., 2008; Deng et al., 2010; Couillard-
Despres et al., 2011; Sahay et al., 2011).
In rodents, hippocampal adult neurogenesis is profoundly
affected by chronically administered opiates. Adult in vivo
exposure to m-opioid receptor (MOR) agonists decreases SGZ
progenitor proliferation, maturation, and survival of new neu-
rons (Eisch et al., 2000;Mandyam et al., 2004; Kahn et al., 2005;
Eisch and Harburg, 2006; Arguello et al., 2009). On the basis of
these observations, it can be hypothesized that alteration in
hippocampal neurogenesis may represent one mechanism by
which opiates may exert long-lasting effects on the neural
circuitry involved in learning, memory, and cognition.
Both preclinical and clinical studies show that tapentadol is
a novel centrally acting analgesic drug that has efficacy
comparable with that of strong opiates in a broad spectrum of
acute and chronic pain conditions, with an improved tolera-
bility profile compared with classic opiates (Tzschentke et al.,
2007, 2009; Kress, 2010; Sloan, 2010; Etropolski et al., 2011;
Riemsma et al., 2011; Hartrick and Rodríguez Hernandez,
2012; Pergolizzi et al., 2012). Tapentadol combines MOR
agonistic activity with norepinephrine reuptake inhibition
(NRI) in a single molecule (Tzschentke et al., 2007; Bee et al.,
2011; Hartrick and Rozek, 2011; Schröder et al., 2011).
Since literature data suggest that norepinephrine (NE) ex-
erts positive modulation on adult hippocampal neurogenesis
(Kulkarni et al., 2002; Jha et al., 2006), we explored whether
the noradrenergic activity of tapentadol may counteract the
negative MOR-mediated action on neurogenesis. In principle,
this counterbalancing effect may result, after long-term treat-
ment in vivo, in less or no dysfunction in adult neurogenesis
and cognitive impairment compared with morphine.
Materials and Methods
Animals. Adult male CD1mice (aged 4–6months) were purchased
from Charles River Laboratories (Calco, Italy). All animals were
maintained in high-efficiency particulate air–filtered Thoren units
(Thoren Caging Systems, Inc., Hazleton, PA) at the University of
Eastern Piedmont animal facility, were kept at three to four per cage,
and had unlimited access to water and food. Care and handling of
animals were performed in accordance with the National Institutes of
Health guidelines and also reviewed and were approved by the local
institutional animal care and use committee.
Drugs. The sources for drugs were as follows: tapentadol HCl
(Grünenthal, Aachen, Germany), morphine sulfate salt pentahydrate
(Sigma-Aldrich, St. Louis, MO), naltrexone HCl (provided by Professor
Paola Sacerdote, University of Milan, Milan, Italy), D-Phe-Cys-Tyr-D-
Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) (Tocris Bioscience, Bristol, UK),
reboxetinemesylate hydrate (Sigma-Aldrich), doxazosinmesylate (Tocris
Bioscience), ICI 118,551 [3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]
butan-2-ol; Tocris Bioscience], CGP 20712A dihydrochloride [1-[2-((3-
carbamoyl-4-hydroxy)phenoxy)ethylamino]-3-[4-(1-methyl-4-trifluoromethyl-
2-imidazolyl)phenoxy]-2-propanol dihydrochloride; Tocris Bioscience],
clonidine hydrochloride and yohimbine hydrochloride (Sigma-Aldrich),
and salbutamol (Prestwick Chemical, Illkirch, France).
Isolation and Culture of Adult Hippocampal Neural Pro-
genitor Cells. For each neurosphere preparation, three adult male
mice (aged 4–6 months) were euthanized by cervical dislocation. The
brains were extracted and hippocampi were isolated under a Zeiss
(Carl Zeiss, Oberkochen, Germany) dissecting microscope using fine
surgical instruments and collected in ice-cold 1,4-piperazinedietha-
nesulfonic acid buffer, pH 7.4, containing 20 mM 1,4-piperazinedie-
thanesulfonic acid, 25 mM glucose, 0.5 M KCl, 0.12 M NaCl
(Sigma-Aldrich), and 100 U/100 mg/ml penicillin/streptomycin solu-
tion (Life Technologies, Monza, Italy). After centrifugation (110g  5
minutes), tissue was digested for 40 minutes at 37°C using the Papain
Dissociation System (Worthington DBA, Lakewood, NJ). Cell sus-
pension was plated onto a 25-cm2 Falcon cell-culture flask (Delchi-
mica Scientific Glassware, Naples, Italy) and cultured as previously
described (Valente et al., 2012). Primary (passage 1, P1) neurospheres
were dissociated after 7–9 days, whereas P2–P30 neurospheres every
5 days in vitro. P3–P30 neurospheres were used for experiments.
Neural Progenitor Cell Differentiation. For differentiation,
neurospheres were dissociated and plated onto laminin-coated (2.5
mg/cm2; Sigma-Aldrich) Laboratory-Tek eight-well Permanox Cham-
ber Slides (Nunc, Wiesbaden, Germany) at a density of 43,750 cells/
cm2 in differentiating medium (Neurobasal-A medium [Life Technol-
ogies] containing B27 supplement, 2 mM L-glutamine, and 100 U/100
mg/ml penicillin/streptomycin). Neural progenitor cells (NPCs) were
treated in the presence of indicated concentrations of drugs or vehicle
for 24 hours. In each experiment, five fields per well (corresponding to
about 150–200 cells per well) were counted using the Eclipse E600
fluorescence microscope (Nikon, Calenzano, Italy) with a 60 objec-
tive. All experiments were run in triplicate using different cell
preparations and were repeated at least three times.
Immunocytochemical Analysis. After fixation, neurosphere-
derived differentiated cells were washed three times in phosphate-
buffered saline (PBS) and permeabilized in PBS containing 0.48% (v/v)
Triton X-100 (Sigma-Aldrich), for 5 minutes at room temperature.
The primary antibodies against microtubule-associated protein-2
(MAP-2; rabbit polyclonal, 1:600; Chemicon, Temecula, CA) and b-III
tubulin (Tuj-1 clone, chicken monoclonal, 1:2000; Aves Laboratories
Inc., Tigard, OR) were incubated for 150minutes at room temperature
in an antibody solution containing 16% (v/v) goat serum. Secondary
antibodies were as follows: Alexa Fluor 555–conjugated goat anti-
rabbit antibody (1:1400; Molecular Probes, Eugene, OR) and Alexa
Fluor 488–conjugated goat anti-chicken antibody (1:1400; Molecular
Probes) in a solution containing 16% (v/v) goat serum. Nuclei were
counterstained with Draq5 (1:2000; Alexis Biochemicals, San Diego,
CA) or Hoechst (0.8 ng/ml; Sigma-Aldrich), diluted in PBS. Slides
were coverslipped with fluorescent mounting medium (DakoCytoma-
tion, Glostrup, Denmark) as an antifading agent. Adobe Photoshop CS
(Adobe Systems Incorporated, San Jose, CA) was used for digital
processing of the images. Only light intensity, brightness, and con-
trast adjustments were applied to improve information.
Morphologic Analysis. To evaluate neurite growth and arbori-
zation, cells were differentiated in vitro for 24 hours in the presence of
drugs or vehicle; thereafter, an immunolocalization with an antibody
against Tuj-1 was performed. Tuj-11 newly generated neurons and
neuroblasts were then grouped based on the absence or presence of
neurites. In the latter case, Tuj-11 cells were also grouped as unipolar
versus bipolar and based on the presence or absence of arborizations. In
each experiment, five fields per well (corresponding to 60–90 Tuj-11 cells
per well) were counted using the Eclipse E600 fluorescence microscope
(Nikon) with a 60 objective. All experiments were run in triplicate
using different cell preparations and were repeated at least three times.
Assessment of Cell Viability. Necrosis evaluation in NPC cul-
tures was performed as previously described (Meneghini et al., 2010).
For apoptosis quantification, the in situ terminal deoxynucleotidyl
transferase–mediated digoxigenin-deoxyuridine nick-end labeling
assay was performed by the In Situ Cell Death detection kit (Roche
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Diagnostic, Monza, Italy), in accordance with the manufacturer’s
instructions. All experiments were run in triplicate using different cell
preparations and were repeated at least three times.
RNA Isolation and Reverse Transcriptase-Polymerase Chain
Reaction Analysis. Total mRNA was extracted from hippocampus
and hippocampal neurospheres (1–3  106 cells) of adult mice by using
the SV Total RNA Isolation System (Promega, Milan, Italy), according
to the manufacturer’s instructions. The cDNA was obtained by using
the ImProm-II Reverse Transcription System kit (Promega). The
primer sequences used for polymerase chain reaction (PCR) amplifica-
tion were as follows: MOR, sense 59-ATACAGGCAGGGGTCCATAG-39
and antisense 59-GTCCATAACACACAGTGATGATGA-39; and norepi-
nephrine transporter (NET), sense 59-CTTCTGGCGCGAATGAAT-39
and antisense 59-CATTGCGTTCCTTCACCACT-39. PCR reactionswere
carried out by using GoTaq Flexi DNA polymerase (Promega) in a final
volume of 25 ml containing 20 ng cDNA, 0.4 mM of each primer, 0.2 mM
dNTPs, and 2.5mMMgCl2. PCR conditions forMOR amplificationwere
as follows: 95°C for 10 minutes; 40 cycles, 94°C for 30 seconds, 57°C for
30 seconds, and 72°C for 30 seconds; and final elongation at 72°C for 10
minutes. PCR conditions forNETamplificationwere as follows: 95°C for
10 minutes; 40 cycles, 94°C for 30 seconds, 61°C for 30 seconds, and
72°C for 45 seconds; and final elongation at 72°C for 10 minutes. PCR
products were run onto 2% agarose gels and bands were visualized by
staining with ethidium bromide (Sigma-Aldrich).
In Vivo Studies. Adult male CD1 mice (aged 3 months) were
randomly distributed into vehicle (n 5 10) and tapentadol treatment
groups (n 5 12). Tapentadol (20 mg/kg body weight) and correspond-
ing vehicle (saline) were administered intraperitoneally daily for 21
days. On the last day of treatment, mice were given three doses of
bromodeoxyuridine (BrdU; 50 mg/kg i.p.), at 2-hour intervals.
Twenty-four hours after the last BrdU dose, half of the mice (n 5 5
and 6 of vehicle- and tapentadol-treated mice, respectively) were
transcardially perfused, and their brains were removed and prepared
for immunohistochemical analysis as previously described (Bonini
et al., 2011). The remaining mice were transcardially perfused 21
days after the last BrdU administration. Coronal brain sections (40-
mm thick) were cut and immunoprocessed for rat monoclonal anti-
BrdU (1:200; Novus Biologicals, Littleton, CO), goat anti–glial
fibrillary acidic protein (GFAP; 1:100; Santa Cruz Biotechnology,
Santa Cruz, CA), and mouse anti–neuronal nuclei (NeuN; 1:150;
Millipore, Billerica, MA) as previously described (Denis-Donini et al.,
2008). For quantification and phenotypic characterization of pro-
liferating and newborn cells, a modified unbiased stereology protocol
was used, as previously reported (Meneghini et al., 2013).
Statistical Analysis. In all in vitro experiments, data are
reported as the mean 6 S.E.M. of at least three experiments in
triplicate. In vivo data are reported as the mean 6 S.D. Data were
analyzed by one-way analysis of variance (ANOVA) followed by the
Tukey’s post hoc test or t test. The statistical significance level was set
for P values ,0.05.
Results
MOR and NET Transcripts Are Expressed in Un-
differentiated Hippocampal Neural Progenitors. In our
experimental setting, NPCs from the adult mouse hippocampus
are grown in the presence of epidermal growth factor and basic
fibroblast growth factor-2 as floating neurospheres and are
phenotypically characterized by the expression of nestin and
SRY-related HMG-box gene 2, markers of undifferentiated
neural progenitors, and by the absence of markers of mature
and immature neurons such as MAP-2, Tuj-1, and doublecortin
(Valente et al., 2012). As shown in Fig. 1, reverse transcription
(RT)-PCR analysis demonstrated that both MOR (Fig. 1A) and
theNET (Fig. 1A) transcriptswere expressed by undifferentiated
hippocampal neurospheres as well as in adult hippocampus,
used as a positive control. Hippocampus and neurosphere RT2
reactions (HP RT2 and NS RT2) served as negative controls.
Morphine Negatively Affects Neuronal Differentia-
tion and Survival of Hippocampal Neural Progenitors
Acting via MOR Activation. Upon removal of growth factors
from the medium, NPCs stop dividing and differentiate giving
rise to neurons, astrocytes, and oligodendrocytes (Cuccurazzu
et al., 2013). To characterize the effects of drugs acting on
neuronal differentiation of hippocampal NPCs, we performed
immunolabeling experiments with antibodies against the neu-
ronal marker MAP-2. Under differentiating conditions, we
evaluated the effect of NPC exposure tomorphine concentrations
(0.3–10 nM), which are consistent with drug affinity values for
mouse MOR [Ki(MOR) 5 2.2 nM]. As shown in Fig. 1B, the drug
significantly decreased the percentage of MAP-21 neurons
(ANOVA, P , 0.05) generated in vitro from adult hippocampal
NPCs, in a concentration-dependent manner. Moreover, the
deleterious effects of morphine on neuronal differentiation were
abolished by naltrexone (10 nM) or by CTOP (1 nM), a highly
selective MOR antagonist [Ki(MOR) 5 1.1 nM]. To further
investigate the negative effects of morphine on neuronal dif-
ferentiation and/or survival of adult hippocampal NPCs and
their progeny, cells were differentiated in vitro in the presence of
vehicle, 10 nM morphine, 10 nM naltrexone, or both morphine
and naltrexone. Thereafter, immunolocalization with a Tuj-1
antibody was performed, since this marker allows us to
effectively immunodecorate all neurites of newly generated
neurons and neuroblasts. Tuj-11 cells were then grouped based
on the absence or presence of neurites, and in the latter case,
were grouped as unipolar versus bipolar, and with or without
neurite arborizations. As shown in Fig. 1, C–G, morphine
negatively affected neurite outgrowth of newly generated cells
from adult NPCs since it significantly decreased the percentage
of bipolar cells (t test,P, 0.05; Fig. 1G) and of arborized unipolar
and bipolar cells (t test, P, 0.05 and P, 0.01, respectively; Fig.
1G) compared with the vehicle. As expected, in parallel, the drug
increased the number of cells without neurites (t test, P , 0.01;
Fig. 1G). In addition, naltrexone abolished the effects of
morphine on neurite outgrowth (t test, P , 0.01; Fig. 1G). We
also investigated the effect of morphine on the apoptotic and
necrotic rate in NPC cultures under differentiating conditions.
As shown in Fig. 1H, compared with vehicle, morphine increased
the percentage of apoptotic nuclei over the total number of cells
in a concentration-dependent manner (ANOVA, P , 0.01).
Conversely, morphine had no effect on necrosis, as measured by
assessing lactate dehydrogenase activity in the culture medium
(data not shown). Cotreatment with naltrexone completely
prevented morphine-mediated effects on apoptotic death (t test,
P, 0.01; Fig. 1H). Similar results were obtained in the presence
of CTOP (Fig. 1H). Importantly, naltrexone or CTOP alone had
no effect on neuronal differentiation (Fig. 1B), neurite outgrowth
(Fig. 1, E and G), and apoptotic rate (Fig. 1H), suggesting that
endogenous opioids were not present in the culture. Overall,
these data suggest that, in the in vitro culture model, morphine
inhibits neuronal differentiation and neurite outgrowth and
increases the apoptotic rate of NPCs and their progeny via MOR
activation.
Tapentadol Negatively Affects Neuronal Differentia-
tion, but Not Survival, of Adult Hippocampal Neural
Progenitors. The effects of tapentadol were investigated
under the same experimental conditions. The drug was tested
over a wide range of concentrations (1 nM to 30 mM) to evaluate
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both its opioidergic and noradrenergic activity. As shown in Fig.
2A, tapentadol produced a U-shaped curve when added to the
culture medium of adult hippocampal NPCs undergoing dif-
ferentiation in vitro. Within the 30–100 nM range, consistent
with MOR affinity values in mouse [Ki(MOR)5 96 nM], the drug
produced a concentration-dependent decrease in the percentage
of newly generated MAP-21 neurons (ANOVA, P , 0.01), with
a maximal effect observed at 100 nM (t test, P, 0.001). Higher
tapentadol concentrations (300 nM to 1 mM) still decreased
neuronal differentiation but drug effects progressively dimin-
ished in a concentration-dependent manner (ANOVA P, 0.01).
Moreover, tapentadol concentrations of 3–30 mM had no effect
on neuronal differentiation of adult mouse hippocampal NPCs.
Surprisingly, unlike morphine, tapentadol did not significantly
increase the apoptotic rate at any tested concentration (Fig. 2B).
Interestingly, tapentadol had significant antiapoptotic effects in
the concentration range of 3–30 mM (t test, P , 0.01; Fig. 2B).
Finally, similar to morphine, the drug had no effect on the
necrotic rate in vitro of NPCs and their progeny, asmeasured by
assessing lactate dehydrogenase activity in the culture medium
(data not shown). When tapentadol was tested for its influence
on neurite outgrowth in NPC cultures under differentiating
conditions, drug concentrations corresponding to 100 and
300 nM showed inhibitory effects, similarly to 10 nMmorphine
Fig. 1. Deleterious effects of morphine on hippocampus-derived adult NPCs and their neuronal progeny. (A) RT-PCR analysis confirmed that bothMOR
and NET transcripts (134- and 118-bp amplicons, respectively) are expressed in hippocampal NPCs grown as neurospheres (NS RT+). The positive
control for RT-PCR experiments was cDNA from adult hippocampus (HP RT+), whereas hippocampus and NS RT2 reactions (HP RT2 and NS RT2)
served as negative controls. The 50-bp DNA ladder was used as a molecular weight marker. (B) Twenty-four–hour treatment with 0.3–10 nM morphine
reduced neuronal differentiation from adult hippocampal NPCs by decreasing the percentage ofMAP-2+ cells compared with vehicle. The antineurogenic
effects of 10 nMmorphine were abolished in the presence of 10 nM naltrexone or 1 nM CTOP. Both antagonists were devoid of effects when added alone.
(C–F) Representative fluorescence microscopy images of Tuj-1 immunolabeling (green) in cells derived from hippocampal NPCs after 24-hour treatment
with vehicle (C), 10 nMmorphine (D), 10 nM naltrexone (E), and 10 nMmorphine and 10 nM naltrexone (F). Nuclei are stained with Draq5 (red). (G) Ten
nanomoles of morphine treatment decreased neurite outgrowth and arborization in newborn Tuj-1+ neuroblasts, as demonstrated by a significant
decrease in the percentage of bipolar cells, arborized unipolar and bipolar cells, and, in parallel, by an increase in the number of cells without neurites.
Naltrexone, inactive alone, abolished the effects of morphine on neurite outgrowth. (H) The percentage of apoptotic cells in NPC cultures increased in
a concentration-dependent manner in the presence of 0.3–10 nM morphine. Proapoptotic effects of 10 nM morphine were totally counteracted by 10 nM
naltrexone and 1 nMCTOP. Both antagonists were devoid of effects when added alone. Data are expressed as the mean6 S.E.M. of three experiments in
triplicate. *P, 0.05; **P, 0.01 versus vehicle-treated cells (t test). HP, hippocampus; MORP, morphine; mw, molecular weight; NS, neurosphere; NTX,
naltrexone; veh, vehicle. Bar, 75 mm in C–F. Original magnification, 400 in C–F.
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(t test, P , 0.01; Fig. 2C). Once again, higher concentrations of
tapentadol (10–30 mM) exerted no effect on neurite outgrowth
and arborization compared with vehicle-treated cells (Fig. 2C).
The Concentration-Dependent Effects of Tapentadol
on NPC Neuronal Differentiation and Survival Are
Mediated by MOR and by a2/b2 Adrenergic Receptors.
We next investigated the contribution of MOR agonism and
NRI activity on tapentadol-mediated effects. As shown in Fig.
3, naltrexone completely abolished the inhibitory effect of low
tapentadol concentrations (50 nM to 1 mM) on both neuronal
differentiation (t test, P , 0.001; Fig. 3A) and neurite
outgrowth (t test, P , 0.01; Fig. 3, B–D).
Functional b2 adrenergic receptors (ARs) are expressed in
our experimental model. Indeed, treatment with 10–300 nM
salbutamol, a selective b2AR agonist, significantly increased
the percentage of newly generated MAP-21 neurons in
a concentration-dependent manner compared with vehicle
(ANOVA, P , 0.05; Fig. 4A). No effect of b2AR activation on
the apoptotic rate of NPCs and their progeny was detected at
any tested salbutamol concentration (data not shown). On the
basis of these observations, we then investigated whether the
effects of tapentadol on neuronal differentiation were de-
pendent on its NRI activity and potentially mediated by b2AR.
We exposed NPC cultures to 1 nM to 30 mM tapentadol in the
presence of 100 nM ICI 118,551, a selective b2AR antagonist,
or the corresponding vehicle. As shown in Fig. 4B, ICI 118,551
had no effect on tapentadol-mediated effects up to a drug
concentration of 1 mM. Within tapentadol concentration range
of 3–30 mM, which has no apparent effect on neuronal
differentiation in vitro, pretreatment with ICI 118,551 signif-
icantly reduced the percentage of MAP-21 newly generated
neurons, when compared with tapentadol alone (t test, P ,
0.05). Similarly, although both 100 nM ICI 118,551 and 30 mM
tapentadol had no effect alone, when added together they
resulted in a significant reduction of neurite outgrowth in Tuj-
11 cells (Fig. 4, C–E), as demonstrated by a decreased
percentage of bipolar cells (t test, P , 0.01; Fig. 4E) and
arborized bipolar cells (t test,P, 0.05; Fig. 4E) and, in parallel,
an increased percentage of cells with no neurites or unipolar (t
test, P , 0.05 and P , 0.001, respectively; Fig. 4E) compared
with vehicle. In addition, 100 nM ICI 118,551 counteracted the
prosurvival effect of 3–30 mM tapentadol (Fig. 4F). We also
evaluated the potential contribution of b1AR activation in
tapentadol-mediated effects. As shown in Fig. 4, G and H, in
the presence of tapentadol 3–30 mM, treatment with 10 nM
CGP 20712A, a selective b1AR antagonist, did not produce
significantly different numbers of MAP-21 neurons (Fig. 4G)
and apoptotic cells (Fig. 4H), compared with tapentadol alone.
Moreover, CGP 20712A per se had no effect on neuronal
differentiation and apoptotic rate when used at 10 nM (Fig. 4,
G and H) and over a wider range of concentrations (0.1–100
nM; data not shown). Since several articles have demonstrated
the involvement of a2AR subtypes in tapentadol-mediated
analgesia (Bee et al., 2011; Hartrick and Rozek, 2011; Schiene
et al., 2011), we then tested the effect of yohimbine (1–100 nM),
a well characterized a2AR antagonist, in our culture model. As
shown in Fig. 5A, 1–3 nM yohimbine was ineffective, whereas
higher drug concentrations (10–100 nM) produced a small, but
statistically significant, increase in the percentage of MAP-21
neurons (P , 0.05), without affecting NPC survival (data not
shown). When an inactive concentration of yohimbine (3 nM)
was added to the culture medium in the presence of 30 mM
tapentadol, the antiapoptotic activity of the tapentadol was
prevented (t test, P , 0.05; Fig. 5B). Conversely, no significant
difference was observed in the number of MAP-21 neurons
generated in vitro when NPCs were treated with 30 mM
tapentadol in the absence or presence of yohimbine (Fig. 5C).
We also evaluated the potential involvement of a1AR in
tapentadol-mediated activity. The effect of the selective a1AR
antagonist doxazosin (0.01 nM to 1 mM) was initially tested in
Fig. 2. Effects of tapentadol on hippocampus-derived NPCs and their
neuronal progeny. (A) Twenty-four–hour treatment of NPCs with a wide
range of tapentadol concentrations (0.001–30 mM) resulted in a character-
istic U-shaped curve on the number of newly born MAP-2+ cells.
Specifically, 0.03–0.5 mM tapentadol reduced neuronal differentiation
from adult hippocampal NPCs by decreasing the percentage of MAP-2+
cells compared with vehicle. (B) Under a wide range of concentrations
(0.001–1 mM), tapentadol had no effect on the apoptotic rate in NPC
cultures. Higher drug concentrations (3–30 mM) exerted an antiapoptotic
effect. (C) Effects of low and high concentrations of tapentadol on neuritic
outgrowth of NPC cultures under differentiating conditions. The results
showed that 100–300 nM tapentadol, similarly to 10 nM morphine,
decreased both neurite outgrowth and arborization in Tuj-1+ neuroblasts,
as demonstrated by a significant decrease in the percentage of bipolar
cells, arborized unipolar and bipolar cells, and by an increase in the
number of cells without neurites. Conversely, 10–30 mM tapentadol had no
effect on neurite outgrowth and arborization in Tuj-1+ cells. Data are
expressed as the mean 6 S.E.M. of three experiments in triplicate. *P ,
0.05; **P , 0.01; ***P , 0.001 versus vehicle-treated cells (t test). MORP,
morphine; TAP, tapentadol; veh, vehicle.
662 Meneghini et al.
 at A
SPET Journals on February 1, 2016
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
our culture model. Starting at 0.1 nM, doxazosin increased, in
a concentration-dependent manner, the percentage of MAP-21
neurons (ANOVA, P , 0.05; Fig. 5D), with its maximal effect
reached at 100 nM, suggesting the presence of an a1AR-mediated
noradrenergic tone in our culture system.No significant difference
was observed in the number of MAP-21 neurons generated in
vitro when NPCs were treated with 30 mM tapentadol in the
absence or presence of doxazosin 0.03 nM, a concentration that per
se has no effect on neurogenesis (Fig. 5E). Moreover, unlike
yohimbine, 0.03 nM doxazosin could not counteract the anti-
apoptotic effect of 30 mM tapentadol (Fig. 5F). To complete our
pharmacological characterization, we then tested clonidine
(1 nM to 1 mM), a commonly used a2AR agonist. Our results
showed that 10–1000 nM clonidine significantly increased the
percentage of MAP-21 neurons compared with vehicle (Fig.
5G). Conversely, clonidine did not affect the apoptotic rate of
NPCs and their progeny at any tested concentration (data not
shown). The proneurogenic effects elicited by clonidine could
be potentially explained by the fact that the drug can act
as a partial agonist at a2AR and as an antagonist at a1AR
(Silva et al., 1996). Altogether, our extensive pharmacological
characterization suggested that at micromolar concentrations,
tapentadol counteracted the negativeMOR-mediated effects on
neurogenesis via b2AR activation, whereas it elicited anti-
apoptotic effects via activation of both b2AR and a2AR.
Since nanomolar (MOR interacting) concentrations of tapen-
tadol had no effect on apoptosis (unlike morphine), we decided
to test the effect of CTOP in the presence of tapentadol.
Although, as expected, 100 nM tapentadol alone had no effect
on apoptosis, MOR blockade by CTOP (1–10 nM) in the
presence of tapentadol resulted in a reduced apoptotic rate
compared with drug alone (Fig. 5H). These data suggest that,
in vitro, the MOR-dependent proapoptotic effects of tapentadol
are also counteracted by antiapoptotic drug–mediated effects.
Morphine-Mediated Antineurogenic and Proapoptotic
Effects on Adult NPCs and Their Progeny Can Be
Counteracted by a Noradrenaline Reuptake Inhibitor.
Overall, our data suggested that the noradrenergic component
in tapentadol has the potential to counteract most of the
deleterious MOR-mediated effects on hippocampal neurogen-
esis. As a proof of concept, we decided to mimic the dual
mechanism of action of tapentadol, by cotreating NPC cultures
withmorphine and reboxetine, anNRI antidepressant drug. As
shown in Fig. 6A, 100 nM reboxetine, which alone promotes
neuronal differentiation of adult hippocampal NPCs, was able
to counteract inhibition of neuronal differentiation elicited
by 10 nM morphine (t test, P , 0.01). More interestingly,
100 nM reboxetine also counteracted the proapoptotic effects of
morphine (t test, P , 0.001; Fig. 6B), even if at that concen-
tration the drug alone has no effect on cell survival.
Chronic Tapentadol Treatment Does Not Negatively
Affect Hippocampal Neurogenesis In Vivo. Adult male
mice (n 5 22) were injected intraperitoneally once daily with
vehicle (saline) or 20 mg/kg tapentadol for a period of 21 days.
At the end of the administration period, mice were injected
with the thymidine analog BrdU (50 mg/kg i.p., three times at
2-hour intervals) to label proliferating cells in the S-phase. A
group of animals (n 5 11) was euthanized 24 hours later,
whereas a second group (n5 11) was euthanized 21 days after
BrdU administration. The number of BrdU-labeled cells in the
SGZ and in the granular cell layer (GCL) within the DG of
vehicle- and tapentadol-treated mice was quantified by a
modified unbiased stereology protocol as previously described
(Denis-Donini et al., 2008). As shown in Fig. 7A, we observed no
significant difference in the absolute number of BrdU1 cells in
the SGZ or GCL of mice treated with 20 mg/kg tapentadol in
the 24-hour group comparedwith vehicle (mean 5886 87.5 and
4886 186.1 BrdU1 cells in the SGZ in vehicle- and tapentadol-
treated mice, respectively; mean 888 6 297.3 and 637 6 165.4
BrdU1 cells in the GCL in vehicle- and tapentadol-treated
mice, respectively). These data confirm that, unlike morphine
(Eisch et al., 2000; Arguello et al., 2009), chronic tapentadol
treatment has no negative effects on the proliferative rate of
adult hippocampal neural progenitors. In the 21-day group, we
Fig. 3. The deleterious effects of low tapentadol concentrations on
neuronal differentiation and neurite outgrowth are MOR mediated. (A)
Naltrexone (10 nM) completely counteracted tapentadol-induced reduc-
tion of MAP2+ cells generated by adult hippocampal NPCs. (B and C)
Representative fluorescence microscopy images of Tuj-1 immunolabeling
(green) in cells derived from hippocampal NPCs after 24-hour treatment
with 300 nM tapentadol in the absence (B) and presence (C) of 10 nM
naltrexone. Nuclei are stained with Draq5 (red). (D) The reduction in
neurite outgrowth and arborization elicited by 300 nM tapentadol was
counteracted in the presence of 10 nM naltrexone. Data are expressed as
the mean 6 S.E.M. of three experiments performed in triplicate. **P ,
0.01; ***P , 0.001 versus vehicle-treated cells (t test). NTX, naltrexone;
TAP, tapentadol; veh, vehicle.
The Novel Analgesic Tapentadol Does Not Impair Adult Neurogenesis 663
 at A
SPET Journals on February 1, 2016
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
Fig. 4. Activation of b2AR mediates tapentadol-dependent effects on neuronal differentiation, neurite outgrowth, and apoptotic rate. (A) Evaluation of
the percentage of MAP-2+ cells in adult hippocampal NPC cultures treated for 24 hours with 10–300 nM salbutamol. The selective b2AR agonist
significantly increased the percentage of newly generated neurons in a concentration-dependent manner. (B) Quantification of the percentage of MAP-2+
cells in adult hippocampal NPCs treated with 0.001–30 mM tapentadol in the absence or presence of 100 nM ICI 118,551, a selective b2AR antagonist.
ICI 118,551, which alone had no effect, significantly reduced the percentage of MAP-2+ cells in the presence of 10–30 mM tapentadol. (A and B) Data are
expressed as the mean 6 S.D. of three experiments in triplicate. *P , 0.05; **P , 0.01; ***P , 0.001 versus vehicle-treated cells; xP , 0.05 versus
tapentadol-treated cells (t test). (C and D) Representative fluorescence microscopy images of Tuj-1 immunolabeling (green) in cells derived from
hippocampal NPCs after 24-hour treatment with 30 mM tapentadol alone (C) or in the presence of 100 nM ICI 118,551 (D). Nuclei are counterstained
with Draq5 (red). (E) Although 30 mM tapentadol and 100 nM ICI118,551 had no effect alone, when added together they resulted in a significant
reduction of neurite outgrowth in Tuj-1+ cells, as demonstrated by a decreased percentage of bipolar and arborized bipolar cells and a parallel increased
percentage of cells with no neurites or unipolar cells compared with vehicle. Data are expressed as the mean percentage 6 S.E.M. of Tuj-1+ cells over
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phenotypically characterized BrdU1 cells by performing a triple
immunolabeling with antibodies raised against BrdU, NeuN (a
marker of mature neurons), and GFAP (a marker of astrocytes).
The number of immunolabeled cells was quantified in the GCL of
mice hippocampi, the region where newly generated cells can
migrate and, if they survive, acquire their neuronal or astroglial
phenotype. Moreover, the total number of BrdU1 cells was
determined to evaluate differences in the survival rate of BrdU-
labeled cells at 3 weeks after their labeling. As shown in Fig. 7B,
the total number of BrdU1 cells was not significantly different in
mice chronically treatedwith 20mg/kg tapentadol comparedwith
vehicle-treated animals, although a trend toward increase was
observed in drug-treated mice (mean 155 6 66.1 and 202 6 74.3
in the SGZ in vehicle- and tapentadol-treated animals, re-
spectively, P 5 0.29; mean 577.6 6 254.1 and 682.7 6 135 in
the GCL in vehicle and tapentadol-treated animals, respectively,
P 5 0.40). When we determined the number of labeled cells that
had become neurons (BrdU1/NeuN1 cells), again no significant
difference was observed between tapentadol- and vehicle-treated
groups in theGCL (mean 5306 258 and 6216 112 in vehicle and
tapentadol-treated animals, respectively, P 5 0.90), as shown in
Fig. 7C. A very small number of proliferating cells in the
hippocampus also undergo differentiation toward the astroglial
lineage. When we counted BrdU1/GFAP1 cells, there was not
a significant difference between tapentadol- and vehicle-treated
mice (data not shown).We decided to evaluate whether there was
any difference between the two treatment groups in end points
correlating with neurogenesis in ventral versus dorsal hippocam-
pus. As shown in Fig. 7D, we observed a higher number, although
not reaching statistical significance, of newneurons in the ventral
hippocampus in tapentadol-treated mice compared with vehicle-
treated mice (mean 262.8 6 140 and 397.3 6 79 BrdU1/NeuN1
cells in vehicle- and tapentadol-treated animals; t test, P 5
0.07). Conversely, no such trend could be seen in the dorsal
hippocampus (mean 267.2 6 128 and 224 6 67 BrdU1/NeuN1
cells in vehicle- and tapentadol-treated animals, respectively,
P5 0.488; Fig. 7D).Webelieve that this trend underlies a positive
effect of chronic tapentadol on neurogenesis in the ventral
hippocampus. Indeed, when intragroup statistical evaluation
was performed, significantly more new neurons were present in
the ventral comparedwith the dorsal hippocampus in tapentadol-
treated mice (t test, P 5 0.0021), whereas no difference was
present between the two subregions in vehicle-treated mice
(t test,P5 0.96; Fig. 7E). Interestingly, this intragroup difference
restricted to the ventral hippocampus was also confirmed for the
late survival of total BrdU1 cells (t test, P5 0.0031; Fig. 7F), but
not for the number of undifferentiated BrdU1/NeuN2/GFAP2
cells (t test, P 5 0.50) or BrdU1/GFAP1 cells (t test, P 5 0.492)
in tapentadol-treated mice (data not shown).
Discussion
Findings correlating long-term use of opiates and cognitive
dysfunction raise the possibility that chronic opiate use may
produce maladaptive plasticity in brain structures involved in
learning andmemory, such as the hippocampus. In rodents, in
vivo exposure to MOR agonists decreases SGZ proliferation
by inhibition of progenitor proliferation, maturation, and
survival of new neurons (Eisch et al., 2000; Mandyam et al.,
2004; Kahn et al., 2005; Eisch and Harburg, 2006; Arguello
et al., 2009). On the basis of these observations, it can be
hypothesized that alterations in hippocampal neurogenesis
may represent one mechanism by which opiates exert long-
lasting effects on the neural circuitry involved with cognition.
Tapentadol is a novel centrally acting analgesic drug that
combines MOR agonistic activity with NRI in a single
molecule (Tzschentke et al., 2007; Bee et al., 2011; Hartrick
and Rozek, 2011; Schröder et al., 2011). When we compared
the effects of tapentadol and morphine on adult hippocampal
NPC cultures, distinct differences between the two molecules
could be observed. Morphine adversely affected neuronal
differentiation, neurite outgrowth, and survival. Pharmaco-
logical blockade by naltrexone and CTOP confirmed that
MOR activation was responsible for the deleterious effects of
morphine. Interestingly, unlike morphine, tapentadol was
devoid of adverse effects on cell survival, although it reduced
neurite outgrowth and the number of newly generated
neurons only within a concentration range known to interact
with MOR and not at higher concentrations that affect NE
reuptake. Extensive pharmacological characterization of the
AR subtypes involved in such effects demonstrated that
tapentadol counteracts MOR-mediated antineurogenic effects
mainly via b2AR receptors. Indeed, in the presence of the
selective b2AR antagonist ICI 118,551, micromolar tapenta-
dol resulted in a significant reduction in the number of
MAP-21 neurons generated by adult NPCs compared with
tapentadol alone. We also showed that the b2AR agonist
salbutamol is indeed proneurogenic on adult hippocampal
NPCs. These findings are in line with the recent observation
by Masuda et al. (2012) that noradrenaline and salmeterol
can increase proliferation of NPCs derived from adult DG via
activation of b2AR. On the basis of our experimental results
with selective antagonists, herein we also suggest that
b1ARs, a1ARs, and a2ARs do not take part in the noradren-
ergic component of tapentadol action that counteracts the
deleterious negative effects of MOR. Gupta et al. (2009)
recently suggested that a1AR, expressed by neural progeni-
tors, could regulate adult neurogenesis both in vivo and in
vitro in a complex manner. In particular, they showed
increased incorporation of BrdU in neurogenic areas of
a1AR overexpressing transgenic mice and wild-type mice
treated with the a1 selective agonist cirazoline, suggesting
a positive effect of that receptor subtype on proliferation.
Moreover, they reported that a1AR stimulation reduced
neuronal differentiation in adult neurosphere cultures. In
line with these observations, we now report that treatment of
adult hippocampal NPCs with the a1AR antagonist doxazosin
effectively promotes neuronal differentiation in vitro. On the
viable cells, and are the result of three experiments performed in triplicate. *P , 0.05; **P , 0.01; ***P , 0.001 versus vehicle-treated cells (t test). (F)
The antiapoptotic effect of 3–10 mM tapentadol was counteracted by 100 nM ICI 118,551. The antagonist alone had no effect. (G and H) The effects of
3–30 mM tapentadol on neuronal differentiation (G) and apoptotic rate (H) were not significantly affected by 10 nM of CGP 20712A, a selective b1AR
antagonist. The antagonist had no effect when tested alone. (F and H) Data are expressed as mean 6 S.D. of three experiments in triplicate. *P , 0.05;
**P , 0.01; ***P , 0.001 versus vehicle-treated cells; xP , 0.05 versus tapentadol-treated cells (t test). Bar, 75 mm in C and D. Original magnification,
400 in C and D. CGP, CGP 20712A; ICI, ICI 118,551; SALB, salbutamol; TAP, tapentadol; w/, presence; w/o, absence.
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other hand, an inactive concentration of doxazosin had no effect
on neuronal differentiation in presence of tapentadol. Similar
results were obtained with the a2AR antagonist yohimbine,
which had no effect on neuronal differentiation in the presence
of micromolar concentrations of tapentadol. The available
literature data suggest that activation of a2AR decreases adult
hippocampal neurogenesis (Yanpallewar et al., 2010). These
conclusions are mainly based on the observation that a2AR
agonists clonidine and guanabenz decrease proliferation and
not differentiation or survival of neural progenitors in vivo
(Yanpallewar et al., 2010). Furthermore, in vivo a2AR blockade
by yohimbine accelerated the neurogenic effects of chronic
imipramine administration. In partial agreement with these
data in our experimental settings, yohimbine, per se, could
produce a small but significant increase in neuronal differen-
tiation. To our surprise, when we tested clonidine in vitro, the
drug promoted neuronal differentiation of adult hippocampal
neural progenitors. Since clonidine Ki values at a2AR are only
Fig. 5. Blockade of a2AR counteracts the antiapoptotic effects elicited by tapentadol. (A) Quantification of the percentage of MAP-2+ cells in adult
hippocampal NPC cultures treated for 24 hours in the presence of 1–100 nM yohimbine, an a2AR antagonist, or vehicle. At higher concentrations (10, 30, or
100 nM), yohimbine resulted in a small but significant increase in neuronal differentiation. (B) Three nanomoles of yohimbine counteracted the
proapoptotic effects of 30 mM tapentadol. (C) Three nanomoles of yohimbine and 30 mM tapentadol had no effect on MAP-2+ cells. (D) Evaluation of the
percentage of MAP-2+ cells in NPC cultures differentiated in the presence of 0.01 nM to 1 mM doxazosin, an a1AR antagonist. Doxazosin significantly
increased the percentage of newly generated neurons, with a maximal effect elicited at 100 nM. (E) An inactive concentration of doxazosin (0.03 nM) had no
effect on neuronal differentiation in the presence of 30mM tapentadol. (F) Doxazosin (0.03 nM) did not prevent the antiapoptotic effect of 30 mM tapentadol.
(G) The percentage of MAP-2+ cells in adult hippocampal NPC cultures treated with the a2AR drug clonidine (1 nM to 1 mM) or vehicle. (H) The selective
MOR antagonist CTOP (1–10 nM) reduced the percentage of apoptotic cells when added in the presence of 100 nM tapentadol. Per se, CTOP and tapentadol
had no effect on the apoptotic rate in culture compared with vehicle-treated cells. Data are expressed as the mean6 S.D. of three experiments in triplicate.
*P , 0.05; **P , 0.01; ***P , 0.001 versus vehicle-treated cells (t test). DOX, doxazosin; TAP, tapentadol; veh, vehicle; YOH, yohimbine.
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10 times lower than those at a1AR and the drug can act as
a partial a2AR agonist and an a1AR antagonist (Silva et al.,
1996), the proneurogenic effects elicited by clonidine in our
culture model may actually be mediated by both a2- and a1AR.
In our culture model, only yohimbine and ICI 118,551, but
not CGP 20712A or doxazosin, could prevent the antiapoptotic
effect of tapentadol, suggesting the involvement of b2- and
a2AR subtypes in such activity. Interestingly, the strong
analgesic effects of the MOR/NRI drug are also a2AR-
mediated in animal models of pain (Tzschentke et al., 2007;
Schröder et al., 2011).
Since there is no evidence of direct interaction of tapentadol
with b2- and a2AR (Tzschentke et al., 2007), at the present
stage of knowledge we propose that the effects of the MOR/
NRI drug on neuronal differentiation and survival of hippo-
campal NPCs may represent an indirect consequence of drug-
mediated blockade of noradrenaline reuptake.
Overall, these data are in agreement with literature reports
demonstrating that the neurotransmitter NE exerts positive
modulation of hippocampal neurogenesis. Indeed, experimen-
tally induced depletion of both brain NE and 5-HT levels,
unlike depletion of 5-HT levels only, reduced both proliferation
and survival of adult-generated neurons in hippocampus (Jha
et al., 2006). Moreover, hippocampal neurogenesis is dramat-
ically reduced in NE-deficient mice (Kulkarni et al., 2002).
To support the idea that the noradrenergic component in
tapentadol has the potential to counteract the adverse MOR-
mediated effects on hippocampal neurogenesis, we showed
that reboxetine, a well characterized NRI antidepressant,
counteracted both antineurogenic and proapoptotic effects of
morphine in vitro in our culture model. On the basis of these in
vitro results, we then tested the effects of chronic tapentadol
administration on adult hippocampal neurogenesis in vivo.
Chronic (21-day) administration of 20mg/kg tapentadol did not
negatively affect cell proliferation and differentiation toward
the neuronal lineage of newly generated cells in hippocampi of
adult mice. In addition, we did not observe any effect of drug
treatment on astrogliogenesis and, more importantly, on
overall survival of new adult-generated cells. The drug dose
of 20 mg/kg was chosen based on several considerations. The
dose is 2–10 times higher than ED50 values for drug analgesic
activity in rodent inflammatory and neuropathic pain models
(Tzschentke et al., 2007; Schiene et al., 2011). Moreover, in vivo
intracerebral microdialysis has demonstrated that at 10 mg/kg
i.p., tapentadol produces an increase in extracellular levels of
NE (1450% of baseline) in the ventral hippocampus of rodents
(Tzschentke et al., 2007). In this study, positive effects of
tapentadol treatment on end points correlating with adult
neurogenesis (neuronal differentiation of adult progenitor cells
and overall survival of progenitors and their progeny) were
specifically restricted to the ventral hippocampus, a subregion
where classic antidepressants, well established positive mod-
ulators of hippocampal neurogenesis, exert their proneuro-
genic effects (Banasr et al., 2006; Tanti et al., 2012).
Altogether, our data support the idea that the noradrener-
gic component in tapentadol has the potential to counteract
the adverse MOR-mediated effects on hippocampal neuro-
genesis in vitro and in vivo. In principle, the tapentadol dual
mechanism of action may result, after long-term drug treat-
ment, in reduced dysfunction in adult neurogenesis compared
withmorphine.We believe that this property of tapentadolmay
be of relevance, since both mechanisms of action contribute to
its analgesic efficacy (Tzschentke et al., 2007; Hartrick and
Rozek, 2011; Schröder et al., 2011).
Our preclinical data highlight the need for a better un-
derstanding of the cellular and molecular effects of opioids on
adult NPCs and their progeny. Potential differences among
different opiates deserve to be carefully investigated. A recent in
vivo study in the rat found that chronically administered meth-
adone did not alter several quantified parameters relevant to
adult hippocampal neurogenesis, including the number of Ki67-,
doublecortin-, or BrdU-immunoreactive cells (Sankararaman
et al., 2012). Methadone is an atypical opiate, since it is a MOR
agonist as well as a noncompetitive N-methyl-D-aspartate
antagonist (Gorman et al., 1997). Whether this pharmacological
property may explain its lack of negative effects on neurogenesis
deserves further investigation sinceN-methyl-D-aspartate antag-
onists have positive effects on hippocampal neurogenesis in ro-
dents (Nacher et al., 2001; Maekawa et al., 2009).
This study, as well as other previous studies with morphine
and methadone, was performed in naïve mice. Interestingly,
several groups demonstrated disruption of hippocampal neu-
roplasticity in rodent models of chronic neuropathic pain
(Terada et al., 2008; Mutso et al., 2012). In particular, Mutso
et al. (2012) demonstrated that chronic neuropathic pain is
Fig. 6. The NRI reboxetine counteracted the deleterious effects of
morphine on neuronal differentiation and survival of NPCs and their
progeny. (A) Quantification of the percentage of MAP-2+ cells in adult
hippocampal NPC cultures treated for 24 hours in presence of 10 nM
morphine, 100 nM reboxetine, and in the presence of both drugs, at the
indicated concentrations. Reboxetine, which alone promoted neuronal
differentiation of adult hippocampal NPCs, was able to counteract
morphine-mediated inhibition of NPC neuronal differentiation. (B) The
effect of reboxetine on morphine-mediated apoptotic death. One-hundred
nanomoles of reboxetine, which alone had no effect on survival, totally
counteracted the proapoptotic effects of 10 nM morphine. Data are
expressed as the mean 6 S.E.M. of three experiments in triplicate. **P ,
0.01; ***P , 0.001 versus vehicle-treated cells (t test). MORP, morphine;
RBX, reboxetine; veh, vehicle.
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associated with abnormalities in hippocampal-mediated behav-
ior, synaptic plasticity, and neurogenesis in rodents. Moreover,
the same authors documented the reduction in hippocampal
volume in patients with chronic pain whose condition has
a predominant neuropathic component. If such hippocampal
changes are indeed related to reduced neuroplasticity, in-
cluding reduced neurogenesis, future studies will need to
address the possibility that they may potentially contribute,
Fig. 7. Chronic (21-day) treatment with tapentadol did not affect hippocampal cell proliferation or generation of new neurons in adult mice. (A)
Quantification of BrdU+ cells in the SGZ and GCL of vehicle-treated and 20mg/kg tapentadol-treatedmice euthanized 24 hours after administration of the
thymidine analog. Cell proliferation did not differ in the two DG subregions. (B) Three weeks after the last BrdU injection, the total number of BrdU+ cells
in the SGZ and GCL was similar in mice treated with vehicle and tapentadol, confirming no difference in cell survival of newly generated cells. (C) The
percentage of newly born neurons, as identified by counting the number of BrdU+/NeuN+ cells, was not different in the SGZ and GCL of vehicle- and
tapentadol-treated animals. (D) Effect of tapentadol and vehicle treatment on the number of newly generated neurons in the GCL of dorsal and ventral
hippocampi. Although not statistically significant (P = 0.07), tapentadol had a more pronounced effect on ventral hippocampus compared with vehicle. No
difference was seen in the dorsal hippocampus. (E) Intragroup effect of vehicle and tapentadol treatment on the number of BrdU+/NeuN+ cells in the GCL of
the dorsal and ventral hippocampus. Unlike vehicle, which did not affect ventral and dorsal neurogenesis differently, significantly more new neurons were
present in the ventral compared with the dorsal hippocampus in the tapentadol-treated group. (F) Intragroup effect of vehicle and tapentadol treatment on
the number of total BrdU+ cells in the GCL of dorsal and ventral hippocampus. Unlike vehicle-treatedmice, in which cell survival was similar in the ventral
and dorsal hippocampus, significantly more cells were present in the ventral compared with the dorsal hippocampus in the tapentadol-treated group. Data
are expressed as the mean 6 S.D. five to six mice per group. **P , 0.01 (t test). hp, hippocampus; TAP, tapentadol; veh, vehicle.
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at least in part, to emotional disturbances, including depressed
mood, which are frequently present in patients suffering from
chronic pain. On the basis of our current data, an analgesic drug
like tapentadol that does not interfere with the generation of
new neuronsmay represent the ideal choice in neuropathic pain
states in which reduced hippocampal neurogenesis may occur
and may in turn diminish the risk not only for cognitive im-
pairment but also for development of mood disorders associ-
ated with chronic pain.
Authorship Contributions
Participated in research design: Tzschentke, Canonico, Grilli.
Conducted experiments: Meneghini, Cuccurazzu, Bortolotto,
Ramazzotti, Ubezio.
Performed data analysis: Meneghini, Cuccurazzu, Bortolotto,
Grilli.
Wrote or contributed to the writing of the manuscript: Meneghini,
Grilli.
References
Aimone JB, Deng W, and Gage FH (2011) Resolving new memories: A critical look at
the dentate gyrus, adult neurogenesis, and pattern separation. Neuron 70:
589–596.
Aimone JB, Wiles J, and Gage FH (2006) Potential role for adult neurogenesis in the
encoding of time in new memories. Nat Neurosci 9:723–727.
Arguello AA, Fischer SJ, Schonborn JR, Markus RW, Brekken RA, and Eisch AJ
(2009) Effect of chronic morphine on the dentate gyrus neurogenic microenviron-
ment. Neuroscience 159:1003–1010.
Banasr M, Soumier A, Hery M, Mocaër E, and Daszuta A (2006) Agomelatine, a new
antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psy-
chiatry 59:1087–1096.
Bee LA, Bannister K, Rahman W, and Dickenson AH (2011) Mu-opioid and norad-
renergic a(2)-adrenoceptor contributions to the effects of tapentadol on spinal
electrophysiological measures of nociception in nerve-injured rats. Pain 152:
131–139.
Bonaguidi MA, Song J, Ming GL, and Song H (2012) A unifying hypothesis on
mammalian neural stem cell properties in the adult hippocampus. Curr Opin
Neurobiol 22:754–761.
Bonini SA, Ferrari-Toninelli G, Uberti D, Montinaro M, Buizza L, Lanni C, Grilli M,
and Memo M (2011) Nuclear factor kB-dependent neurite remodeling is mediated
by Notch pathway. J Neurosci 31:11697–11705.
Cipolli C and Galliani I (1987) Addiction time and intellectual impairment in heroin
users. Psychol Rep 60:1099–1105.
Couillard-Despres S, Iglseder B, and Aigner L (2011) Neurogenesis, cellular plas-
ticity and cognition: the impact of stem cells in the adult and aging brain—a mini-
review. Gerontology 57:559–564.
Cuccurazzu B, Bortolotto V, Valente MM, Ubezio F, Koverech A, Canonico PL,
and Grilli M (2013) Upregulation of mGlu2 receptors via NF-kB p65 acetylation is
involved in the Proneurogenic and antidepressant effects of acetyl-l-carnitine.
Neuropsychopharmacology 38:2220–2230.
Deng W, Aimone JB, and Gage FH (2010) New neurons and new memories: how does
adult hippocampal neurogenesis affect learning and memory?Nat Rev Neurosci 11:
339–350.
Denis-Donini S, Dellarole A, Crociara P, Francese MT, Bortolotto V, Quadrato G,
Canonico PL, Orsetti M, Ghi P, and Memo M et al. (2008) Impaired adult neuro-
genesis associated with short-term memory defects in NF-kappaB p50-deficient
mice. J Neurosci 28:3911–3919.
Eisch AJ, Barrot M, Schad CA, Self DW, and Nestler EJ (2000) Opiates inhibit
neurogenesis in the adult rat hippocampus. Proc Natl Acad Sci USA 97:7579–7584.
Eisch AJ and Harburg GC (2006) Opiates, psychostimulants, and adult hippocampal
neurogenesis: Insights for addiction and stem cell biology. Hippocampus 16:
271–286.
Etropolski M, Kelly K, Okamoto A, and Rauschkolb C (2011) Comparable efficacy and
superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol
compared with oxycodone hydrochloride. Adv Ther 28:401–417.
Gorman AL, Elliott KJ, and Inturrisi CE (1997) The d- and l-isomers of methadone
bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in
rat forebrain and spinal cord. Neurosci Lett 223:5–8.
Gruber SA, Silveri MM, and Yurgelun-Todd DA (2007) Neuropsychological con-
sequences of opiate use. Neuropsychol Rev 17:299–315.
Guerra D, Solé A, Camí J, and Tobeña A (1987) Neuropsychological performance in
opiate addicts after rapid detoxification. Drug Alcohol Depend 20:261–270.
Gupta MK, Papay RS, Jurgens CW, Gaivin RJ, Shi T, Doze VA, and Perez DM (2009)
alpha1-Adrenergic receptors regulate neurogenesis and gliogenesis. Mol Pharma-
col 76:314–326.
Hartrick CT and Rozek RJ (2011) Tapentadol in pain management: a m-opioid re-
ceptor agonist and noradrenaline reuptake inhibitor. CNS Drugs 25:359–370.
Hartrick CT and Rodríguez Hernandez JR (2012) Tapentadol for pain: a treatment
evaluation. Expert Opin Pharmacother 13:283–286.
Højsted J, Kurita GP, Kendall S, Lundorff L, de Mattos Pimenta CA, and Sjøgren P
(2012) Non-analgesic effects of opioids: the cognitive effects of opioids in chronic
pain of malignant and non-malignant origin. An update. Curr Pharm Des 18:
6116–6122.
Jha S, Rajendran R, Davda J, and Vaidya VA (2006) Selective serotonin depletion does
not regulate hippocampal neurogenesis in the adult rat brain: differential effects of
p-chlorophenylalanine and 5,7-dihydroxytryptamine. Brain Res 1075:48–59.
Kahn L, Alonso G, Normand E, and Manzoni OJ (2005) Repeated morphine treat-
ment alters polysialylated neural cell adhesion molecule, glutamate decarboxylase-
67 expression and cell proliferation in the adult rat hippocampus. Eur J Neurosci
21:493–500.
Kempermann G, Gast D, Kronenberg G, Yamaguchi M, and Gage FH (2003) Early
determination and long-term persistence of adult-generated new neurons in the
hippocampus of mice. Development 130:391–399.
Kempermann G, Jessberger S, Steiner B, and Kronenberg G (2004) Milestones of
neuronal development in the adult hippocampus. Trends Neurosci 27:447–452.
Kendall SE, Sjøgren P, Pimenta CA, Højsted J, and Kurita GP (2010) The cognitive
effects of opioids in chronic non-cancer pain. Pain 150:225–230.
Kress HG (2010) Tapentadol and its two mechanisms of action: is there a new
pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain 14:
781–783.
Kulkarni VA, Jha S, and Vaidya VA (2002) Depletion of norepinephrine decreases the
proliferation, but does not influence the survival and differentiation, of granule cell
progenitors in the adult rat hippocampus. Eur J Neurosci 16:2008–2012.
Kurita GP, Sjøgren P, Ekholm O, Kaasa S, Loge JH, Poviloniene I, and Klepstad P
(2011) Prevalence and predictors of cognitive dysfunction in opioid-treated patients
with cancer: a multinational study. J Clin Oncol 29:1297–1303.
Maekawa M, Namba T, Suzuki E, Yuasa S, Kohsaka S, and Uchino S (2009) NMDA
receptor antagonist memantine promotes cell proliferation and production of ma-
ture granule neurons in the adult hippocampus. Neurosci Res 63:259–266.
Mandyam CD, Norris RD, and Eisch AJ (2004) Chronic morphine induces premature
mitosis of proliferating cells in the adult mouse subgranular zone. J Neurosci Res
76:783–794.
Masuda T, Nakagawa S, Boku S, Nishikawa H, Takamura N, Kato A, Inoue T,
and Koyama T (2012) Noradrenaline increases neural precursor cells derived from
adult rat dentate gyrus through b2 receptor. Prog Neuropsychopharmacol Biol
Psychiatry 36:44–51.
Meneghini V, Bortolotto V, Francese MT, Dellarole A, Carraro L, Terzieva S,
and Grilli M (2013) High-mobility group box-1 protein and b-amyloid oligomers
promote neuronal differentiation of adult hippocampal neural progenitors via re-
ceptor for advanced glycation end products/nuclear factor-kB axis: relevance for
Alzheimer’s disease. J Neurosci 33:6047–6059.
Meneghini V, Francese MT, Carraro L, and Grilli M (2010) A novel role for the
receptor for advanced glycation end-products in neural progenitor cells derived
from adult subventricular zone. Mol Cell Neurosci 45:139–150.
Miladi Gorji H, Rashidy-Pour A, and Fathollahi Y (2008) Effects of morphine de-
pendence on the performance of rats in reference and working versions of the water
maze. Physiol Behav 93:622–627.
Mutso AA, Radzicki D, Baliki MN, Huang L, Banisadr G, Centeno MV, Radulovic J,
Martina M, Miller RJ, and Apkarian AV (2012) Abnormalities in hippocampal
functioning with persistent pain. J Neurosci 32:5747–5756.
Nacher J, Rosell DR, Alonso-Llosa G, and McEwen BS (2001) NMDA receptor an-
tagonist treatment induces a long-lasting increase in the number of proliferating
cells, PSA-NCAM-immunoreactive granule neurons and radial glia in the adult rat
dentate gyrus. Eur J Neurosci 13:512–520.
Pergolizzi J, Alegre C, Blake D, Alén JC, Caporali R, Casser HR, Correa-Illanes G,
Fernandes P, Galilea E, and Jany R et al. (2012) Current considerations for the
treatment of severe chronic pain: the potential for tapentadol. Pain Pract 12:
290–306.
Pu L, Bao GB, Xu NJ, Ma L, and Pei G (2002) Hippocampal long-term potentiation is
reduced by chronic opiate treatment and can be restored by re-exposure to opiates.
J Neurosci 22:1914–1921.
Riemsma R, Forbes C, Harker J, Worthy G, Misso K, Schäfer M, Kleijnen J,
and Stürzebecher S (2011) Systematic review of tapentadol in chronic severe pain.
Curr Med Res Opin 27:1907–1930.
Sahay A, Wilson DA, and Hen R (2011) Pattern separation: a common function for
new neurons in hippocampus and olfactory bulb. Neuron 70:582–588.
Sankararaman A, Masiulis I, Richardson DR, Andersen JM, Mørland J, and Eisch AJ
(2012) Methadone does not alter key parameters of adult hippocampal neuro-
genesis in the heroin-naïve rat. Neurosci Lett 516:99–104.
Schiene K, De Vry J, and Tzschentke TM (2011) Antinociceptive and antihyperalgesic
effects of tapentadol in animal models of inflammatory pain. J Pharmacol Exp Ther
339:537–544.
Schröder W, Tzschentke TM, Terlinden R, De Vry J, Jahnel U, Christoph T,
and Tallarida RJ (2011) Synergistic interaction between the two mechanisms of
action of tapentadol in analgesia. J Pharmacol Exp Ther 337:312–320.
Seri B, García-Verdugo JM, Collado-Morente L, McEwen BS, and Alvarez-Buylla A
(2004) Cell types, lineage, and architecture of the germinal zone in the adult
dentate gyrus. J Comp Neurol 478:359–378.
Shors TJ, Miesegaes G, Beylin A, Zhao M, Rydel T, and Gould E (2001) Neurogenesis
in the adult is involved in the formation of trace memories. Nature 410:372–376.
Silva EG, Feres T, Vianna LM, Okuyama P, and Paiva TB (1996) Dual effect of
clonidine on mesenteric artery adrenoceptors: agonistic (alpha-2) and antagonistic
(alpha-1). J Pharmacol Exp Ther 277:872–876.
Sloan P (2010) Tapentadol for acute and chronic pain. Expert Opin Pharmacother 11:
1783–1785.
Spain JW and Newsom GC (1991) Chronic opioids impair acquisition of both radial
maze and Y-maze choice escape. Psychopharmacology (Berl) 105:101–106.
Tanti A, Rainer Q, Minier F, Surget A, and Belzung C (2012) Differential environ-
mental regulation of neurogenesis along the septo-temporal axis of the hippo-
campus. Neuropharmacology 63:374–384.
Terada M, Kuzumaki N, Hareyama N, Imai S, Niikura K, Narita M, Yamazaki M,
Suzuki T, and Narita M (2008) Suppression of enriched environment-induced
neurogenesis in a rodent model of neuropathic pain. Neurosci Lett 440:314–318.
The Novel Analgesic Tapentadol Does Not Impair Adult Neurogenesis 669
 at A
SPET Journals on February 1, 2016
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
Tzschentke TM, Christoph T, Kögel B, Schiene K, Hennies HH, Englberger W,
Haurand M, Jahnel U, Cremers TI, and Friderichs E et al. (2007) (-)-(1R,2R)-3-(3-
dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl):
a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-
spectrum analgesic properties. J Pharmacol Exp Ther 323:265–276.
Tzschentke TM, Jahnel U, Kogel B, Christoph T, Englberger W, De Vry J, Schiene K,
Okamoto A, Upmalis D, and Weber H et al. (2009) Tapentadol hydrochloride:
a next-generation, centrally acting analgesic with two mechanisms of action in
a single molecule. Drugs Today (Barc) 45:483–496.
Valente MM, Bortolotto V, Cuccurazzu B, Ubezio F, Meneghini V, Francese MT,
Canonico PL, and Grilli M (2012) a2d ligands act as positive modulators of adult
hippocampal neurogenesis and prevent depression-like behavior induced by
chronic restraint stress. Mol Pharmacol 82:271–280.
Yanpallewar SU, Fernandes K, Marathe SV, Vadodaria KC, Jhaveri D, Rommel-
fanger K, Ladiwala U, Jha S, Muthig V, and Hein L et al. (2010) Alpha2-
adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral
effects of chronic antidepressant treatment. J Neurosci 30:1096–1109.
Zhao C, Deng W, and Gage FH (2008) Mechanisms and functional implications of
adult neurogenesis. Cell 132:645–660.
Address correspondence to: Mariagrazia Grilli, Laboratory of Neuro-
plasticity and Pain, Department of Pharmaceutical Sciences, University of
Eastern Piedmont Amedeo Avogadro, Via Bovio 6, 28100 Novara, Italy. E-mail:
grilli@pharm.unipmn.it
670 Meneghini et al.
 at A
SPET Journals on February 1, 2016
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
